Pioneering Innovation at AbbVie’s R&D Sites

North Chicago Home to AbbVie’s world headquarters, the North Chicago campus sits on 570 acres and brings together the full spectrum of research and development from the initial idea to the finished product. Teams advance work across all therapeutic areas: immunology, neuroscience, oncology,  aesthetics and specialty medicine. This campus is also home to our Genomics Research Center,  which translates insights from large human-derived datasets into a more personalized approach to medicine. By integrating discovery research, development sciences, regulatory affairs, clinical sciences, development, clinical development operations, medical affairs, Health Impact, manufacturing and many more expert areas, our state-of-the-art facilities in Lake County serve as a strategic hub for tackling some of the world’s most complex diseases.

San Francisco Our South San Francisco site is a state-of-the-art facility with 480,000 square feet of R&D labs and office space. The campus advances oncology discovery and early development while expanding external innovation through AbbVie Ventures. With core capabilities in biologics, genetic medicine, precision medicine and artificial intelligence, the campus supports access to emerging technologies that advance our pipeline. Take a virtual tour of our South San Francisco campus on our Bay Area Opportunities page: www.abbvie.com/join-us/bay-area-opportunities.

Irvine As pioneers in the field of aesthetic medicine, our Irvine campus spans 54 acres and is home to the research, development and manufacturing of science-based products and treatments designed to address patients’ aesthetic goals. Teams in Irvine also support research and development in eye care, neuropsychiatry and migraine.

San Diego Located in a leading innovation hub, this site is committed to developing transformative medicines with a first-in-class targeted lipid nanoparticle platform.

Worcester Home to our largest Massachusetts site, Worcester has led drug discovery, development sciences and biologics research for more than 30 years. The campus spans 30 acres and more than 500,000 square feet of space. Core capabilities include biotherapeutics and genetic medicine.

Cambridge Our two Cambridge sites advance drug discovery and development in neuroscience and immunology. With a broad range of discovery, development and external innovation expertise, including AbbVie Ventures, teams in Cambridge contribute across the research and development function.

Waltham Located in the greater Boston life sciences ecosystem, our Waltham colleagues focus on advancing industry-leading oncology research and development and antibody-drug conjugate therapies. 

Branchburg Our Branchburg site has multiple functions spanning Medical Affairs, Health Impact, Regulatory Affairs, Clinical Development and Development Sciences.

Florham Park Situated in a top-tier life sciences hub, our Florham Park campus focuses on research and development with additional functions representing Medical Affairs and Health Impact, Regulatory Affairs and Clinical Development.

Madison Our Madison site advances novel oral peptide therapeutics, supporting AbbVie’s drug discovery engine across our core therapeutic areas. 

Ludwigshafen With 140 years of research, development and operations heritage, our Ludwigshafen site supports early research and clinical development. As our second-largest R&D site globally, it is a center of excellence for neuroscience research, with a focus on Alzheimer’s and Parkinson’s disease, and supports immunology research. Watch a virtual tour of Ludwigshafen labs on YouTube: https://www.youtube.com/watch?v=bUG4YYs3mEo.

Pringy Located about 25 miles south of Geneva, Switzerland, our Pringy facility integrates research and development with operations and focuses on delivering innovations in filler solutions, prefilled syringe and medical device technology.

Oxford Located in Europe’s rapidly growing life sciences cluster, AbbVie’s DJS Antibodies site houses AbbVie Ventures, is pioneering human reverse translation research and advancing next-generation novel therapeutic antibody platforms that support innovation across our pipeline.

Shanghai Located near Zhangjiang Science City and within reach of the Suzhou and Nanjing biotech hubs, our Shanghai site supports early- to late-stage clinical development across our therapeutic areas, with expertise spanning discovery and development. AbbVie Ventures and Search and Evaluation teams further strengthen local and global partnerships to accelerate access to emerging science and technologies.

Tokyo Our Japan R&D site is home to our full clinical development capabilities. To obtain new drug application (NDA) approvals for Japanese patients, we conduct Phase 1 through Phase 4 clinical trials in Japan. We perform strategic clinical planning for each of our core focus areas to develop Japan-specific development strategies aligned with global programs.